Procter & Gamble Health Ltd
Procter & Gamble Health Ltd, formerly
Merck Ltd, manufactures and markets
vitamins, minerals, supplements and
other healthcare products under brands including Neurobion, Livogen, Seven
Seas, Evion, Polybion and Nasivion.
It is part of the US-based P&G Group
and operates a plant at Usgaon, Goa[1]
- Market Cap ₹ 9,278 Cr.
- Current Price ₹ 5,590
- High / Low ₹ 6,975 / 4,700
- Stock P/E 26.0
- Book Value ₹ 396
- Dividend Yield 2.77 %
- ROCE 83.9 %
- ROE 61.9 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 42.6%
- Company has been maintaining a healthy dividend payout of 87.1%
Cons
- Stock is trading at 14.1 times its book value
- The company has delivered a poor sales growth of 0.76% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 9m | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 940 | 993 | 698 | 849 | 927 | 1,356 | 1,009 | 1,114 | 1,230 | 1,151 | 934 | 1,408 | 1,491 | |
| Sales growth | +8% | +6% | -30% | +22% | +9% | +60% | -26% | +10% | +10% | -6% | -24% | +51% | +16% |
| 855 | 877 | 621 | 701 | 723 | 1,037 | 762 | 846 | 905 | 845 | 616 | 949 | 992 | |
| Operating Profit | 85 | 116 | 77 | 148 | 204 | 319 | 246 | 268 | 325 | 307 | 319 | 459 | 498 |
| OPM % | 9% | 12% | 11% | 17% | 22% | 24% | 24% | 24% | 26% | 27% | 34% | 33% | 33% |
| 22 | 24 | 74 | 768 | 48 | 66 | 18 | 13 | 18 | -5 | 10 | 15 | 48 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 |
| Depreciation | 23 | 25 | 19 | 21 | 17 | 29 | 30 | 27 | 28 | 27 | 17 | 24 | 24 |
| Profit before tax | 83 | 115 | 132 | 895 | 234 | 355 | 233 | 253 | 314 | 273 | 312 | 450 | 521 |
| Tax % | 36% | 31% | 29% | 6% | 32% | 28% | 24% | 24% | 27% | 26% | 25% | 27% | |
| 54 | 79 | 94 | 839 | 159 | 254 | 177 | 193 | 229 | 201 | 234 | 327 | 380 | |
| EPS in Rs | 32.27 | 47.67 | 56.57 | 505.27 | 95.64 | 153.07 | 106.51 | 115.98 | 138.24 | 121.08 | 141.22 | 196.94 | 228.83 |
| Dividend Payout % | 23% | 23% | 27% | 87% | 0% | 150% | 122% | 45% | 69% | 215% | 89% | 104% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 1% |
| 3 Years: | 8% |
| TTM: | 16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 5% |
| 3 Years: | 19% |
| TTM: | 16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 2% |
| 3 Years: | 3% |
| 1 Year: | -4% |
| Return on Equity | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 35% |
| 3 Years: | 43% |
| Last Year: | 62% |
Balance Sheet
Figures in Rs. Crores
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 575 | 647 | 717 | 1,524 | 800 | 890 | 687 | 600 | 734 | 522 | 520 | 508 | 641 |
| 0 | 0 | 0 | 0 | 0 | 0 | 8 | 3 | 12 | 10 | 8 | 9 | 7 | |
| 192 | 215 | 258 | 219 | 250 | 269 | 275 | 269 | 338 | 247 | 250 | 308 | 349 | |
| Total Liabilities | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 841 | 1,015 |
| 132 | 111 | 115 | 104 | 101 | 101 | 104 | 112 | 144 | 128 | 116 | 102 | 102 | |
| CWIP | 7 | 30 | 9 | 17 | 11 | 21 | 39 | 41 | 32 | 6 | 11 | 14 | 10 |
| Investments | 42 | 28 | 70 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 603 | 711 | 797 | 1,639 | 954 | 1,053 | 843 | 736 | 925 | 660 | 667 | 726 | 902 | |
| Total Assets | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 841 | 1,015 |
Cash Flows
Figures in Rs. Crores
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 83 | 107 | 54 | -130 | 235 | 247 | 170 | 236 | 228 | 169 | 338 | ||
| -68 | -75 | -48 | 1,270 | 165 | -32 | -26 | -22 | -7 | 10 | 1 | ||
| -12 | -15 | -22 | -30 | -883 | -387 | -289 | -98 | -418 | -235 | -344 | ||
| Net Cash Flow | 4 | 17 | -16 | 1,109 | -483 | -172 | -145 | 116 | -197 | -56 | -5 | |
| Free Cash Flow | 38 | 75 | 24 | -157 | 212 | 196 | 132 | 198 | 207 | 168 | 323 | |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 136% | 138% | 147% | 117% | 106% | 128% | 87% | 100% | 102% | 78% | 96% |
Ratios
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 49 | 39 | 64 | 28 | 30 | 26 | 22 | 27 | 34 | 27 | 57 | 43 |
| Inventory Days | 140 | 145 | 243 | 154 | 139 | 113 | 138 | 124 | 136 | 120 | 152 | 137 |
| Days Payable | 55 | 67 | 128 | 124 | 106 | 105 | 209 | 185 | 239 | 184 | 239 | 192 |
| Cash Conversion Cycle | 134 | 118 | 179 | 58 | 63 | 34 | -49 | -34 | -69 | -37 | -30 | -13 |
| Working Capital Days | 69 | 52 | 94 | 42 | 22 | 23 | 7 | 17 | 15 | 19 | 48 | 30 |
| ROCE % | 15% | 18% | 16% | 78% | 20% | 29% | 29% | 38% | 45% | 45% | 48% | 84% |
Insights
In beta| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees count |
|
||||||||||
| Number of Countries Exported To count |
|||||||||||
| Total Exports INR crores |
|||||||||||
| Pharmacy Distribution Reach number of pharmacies |
|||||||||||
| HCP (Healthcare Professional) Coverage count of doctors |
|||||||||||
| Productivity Savings INR crores |
|||||||||||
| Volume Growth % |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Intimation Regarding Ease Of Doing Investment - Special Window For Transfer And Dematerialization
- SEBI special window for physical share transfer relodgement extended to February 4, 2027; RTA office moves December 1, 2026.
-
Intimation For Change In Corporate Office Address Of Registrar And Share Transfer Agent (RTA)
- KFin Technologies shifts corporate office from 1 December 2026; company's registered office unchanged.
-
Press Release
- Q2 FY26 sales rose 18% to ₹376 crore; PAT increased 26% to ₹112 crore.
- Outcome Of Board Meeting For The Quarter Ended September 30, 2026
-
Board Meeting Outcome for Outcome For The Board Meeting Held On November 2, 2026
- Board approved unaudited Q2/H1 FY27 results for quarter and half-year ended September 30, 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2013
from nse
Concalls
-
Sep 2026PPT
-
Jun 2026Transcript
-
Jun 2025Transcript PPT
-
Dec 2023PPT
-
Nov 2022PPT
-
May 2018PPT
Background:[1]
The company was incorporated as Merck Ltd
in 1967 and acquired by P&G in 2018. Procter
& Gamble Overseas India BV holds 51.82%,
while The Procter & Gamble Company, USA
is the ultimate parent. It uses group shared services, pays royalties and sells products
to fellow P&G companies.[2]